Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 2, 2012, Pages 173-185

  Gish, Robert G ^a   Lencioni, Riccardo ^b   Di Bisceglie, Adrian M ^c   Raoul, Jean Luc ^d   Mazzaferro, Vincenzo ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUT PAOLI CALMETTES   (France)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

hepatocellular carcinoma; hepatologist; interventional radiologist; medical oncologist; multidisciplinary team; natural history; outcomes; surgical oncologist; targeted therapy; treatment

Indexed keywords

PLACEBO; RADIOISOTOPE; SORAFENIB;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; BEDTIME DOSAGE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HAND FOOT SYNDROME; HEALTH PERSONNEL ATTITUDE; HUMAN; LIVER CELL CARCINOMA; MICROWAVE THERAPY; MORNING DOSAGE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR ABLATION;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84858021301     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.105     Document Type: Review

References (81)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin. 60(5), 277-300 (2010).
3. Thompson Coon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: Systematic review and economic analysis. Health Technol. Assess. 11(34), 1-206 (2007).
4. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127(5 Suppl1), S5-S16 (2004). (Pubitemid 39423365)
5. Sherman M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 30(1), 3-16 (2010).
6. Cpocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F. EUROCARE working group. Hepatocellular carcinoma: Trends of incidence and survival in Europe and the United States at the end of the 20th century. Am. J. Gastroenterol. 102(8), 1661-1670 (2007). (Pubitemid 47206702)
7. McCracken M, Olsen M, Chen MS Jr et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin. 57(4), 190-205 (2007). (Pubitemid 47312080)
8. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig. Dis. 27(2), 80-92 (2009).
9. Amarapurkar D, Han KH, Chan HL, Ueno Y. Asia-Pacific working party on prevention of hepatocellular carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific region. J. Gastroenterol. Hepatol. 24(6), 955-961 (2009).
10. Poon D, Anderson BO, Chen LT et al. Asian oncology summit. Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian oncology summit 2009. Lancet Oncol. 10(11), 1111-1118 (2009).
11. Shariff MI, Cox IJ, Gomaa AI et al. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol. 3(4), 353-367 (2009).
12. Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur. Rev. Med. Pharmacol. Sci. 14(4), 352-355 (2010).
13. Tiribelli C, Melato M, Crocé LS, Giarelli L, Okuda K, Ohnishi K. Prevalence of hepatocellular carcinoma and relation to cirrhosis: Comparison of two different cities of the world - Trieste, Italy, and Chiba, Japan. Hepatology 10(6), 998-1002 (1989). (Pubitemid 20341090)
14. Colombo M. The role of hepatitis C virus in hepatocellular carcinoma. Recent Results Cancer Res. 154, 337-344 (1998).
15. Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (review). Int. J. Oncol. 15(2), 373-379 (1999).
16. Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. Management of chronic hepatitis C in veterans: The potential of integrated care models. Am. J. Gastroenterol. 103(7), 1810-1823 (2008).
17. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003). (Pubitemid 37518510)
18. Schwartz ME, Sung M, Mor E et al. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J. Am. Coll. Surg. 180(5), 596-603 (1995).
19. Van Cleave J, Devine P, Odom-Ball P. Multidisciplinary care of hepatocellular carcinoma. Cancer Pract. 7(6), 302-308 (1999). (Pubitemid 29526489)
20. Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 13(9 Pt 2), S259-S263 (2002).
21. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: The BCLC update and future prospects. Semin. Liver Dis. 30(1), 61-74 (2010).
22. Gish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol. Hepatol. (NY) 6(3 SUPPL6), 1-16 (2010).
23. Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann. Surg. 247(4), 666-673 (2008). (Pubitemid 351440618)
24. Taylor C, Munro AJ, Glynne-Jones R et al. Multidisciplinary team working in cancer: What is the evidence? BMJ 340, c951 (2010).
25. Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: Modeling internal and external influences on cancer care quality. J. Natl Cancer Inst. Monogr. 2010(40), 72-80 (2010).
26. Chang TT, Sawhney R, Monto A et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 10(6), 405-411 (2008).
27. Verslype C, Van Cutsem E, Dicato M et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on gastrointestinal cancer, Barcelona, 2008. Ann. Oncol. 20(SUPPL7), vii1-vii6 (2009).
28. Bruix J, Sherman M. Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005).
29. Llovet JM, Di Bisceglie AM, Bruix J et al. Panel of experts in HCC-design clinical trials. Design and end points of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100(10), 698-711 (2008).
30. Martin RC II, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg. Oncol. Clin. N. Am. 11(1), 193-205 (2002). (Pubitemid 34031226)
31. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther. 23(11), 1535-1547 (2006). (Pubitemid 43727460)
32. Yamamoto K, Imamura H, Matsuyama Y et al. AFP, AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J. Gastroenterol. 45(12), 1272-1282 (2010).
33. Beppu T, Sugimoto K, Shiraki K et al. Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int. J. Mol. Med. 26(3), 425-433 (2010).
34. Zhang XF, Lai EC, Kang XY et al. Lens culinaris agglutinin-reactive fraction of a-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann. Surg. Oncol. 18(8), 2218-2223 (2011).
35. Yamashiki N, Sugawara Y, Tamura S et al. Diagnostic accuracy of a-fetoprotein and des-g-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatol. Res. 41(12), 1199-1207 (2011).
36. Sterling RK, Wright EC, Morgan TR et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am. J. Gastroenterol. 107(1), 64-74 (2012).
37. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 242(2), 151-167 (2006). (Pubitemid 44485315)
38. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase 2 study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006). (Pubitemid 46630787)
39. Llovet JM, Ricci S, Mazzaferro V et al. SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N. Engl J. Med. 359(4), 378-390 (2008).
40. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A Phase 3 randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
41. Keating GM, Santoro A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 69(2), 223-240 (2009).
42. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: The SHARP trial. Expert Rev. Anticancer Ther. 9(6), 739-745 (2009).
43. Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: Where do we go from here? Hepatology 52(1), 360-369 (2010).
44. Zhu AX. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin. Investig. Drugs 19(5), 663-672 (2010).
45. Donckier V, Van Laethem JL, Van Gansbeke D et al. New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J. Surg. Oncol. 84(1), 36-44 (2003). (Pubitemid 37075693)
46. Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br. J. Surg. 90(1), 33-41 (2003). (Pubitemid 37040968)
47. Laurent A, Cherqui D, Lesurtel M, Brunetti F, Tayar C, Fagniez PL. Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease. Arch. Surg. 138(7), 763-769 (2003). (Pubitemid 36858156)
48. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-699 (1996). (Pubitemid 26079803)
49. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 19(3), 329-338 (1999).
50. Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A large case cohort study. Hepatol. Int. 4(1), 396-405 (2009).
51. Changchien CS, Chen CL, Yen YH et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: Prognostic features, treatment outcome, and survival. J. Gastroenterol. 43(2), 159-170 (2008).
52. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28(3), 751-755 (1998).
53. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 31(4), 840-845 (2000).
54. Leung TW, Tang AM, Zee B et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 94(6), 1760-1769 (2002). (Pubitemid 34241115)
55. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 38(3), 207-215 (2003). (Pubitemid 36527122)
56. Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 40(6), 1396-1405 (2004). (Pubitemid 39657014)
57. Nathan H, Bridges JF, Schulick RD et al. Understanding surgical decision making in early hepatocellular carcinoma. J. Clin. Oncol. 29(6), 619-625 (2011).
58. Mazzaferro V, Llovet JM, Miceli R et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 10(1), 35-43 (2009).
59. Borentain P, Gregoire E, Hardwigsen J et al. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 35(3), 234-236 (2011).
60. Palma LD. Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Br. J. Radiol. 71(848), 808-818 (1998).
61. Cabrera R, Nelson DR. Review article: The management of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31(4), 461-476 (2010).
62. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: An update. Expert Rev. Anticancer Ther. 10(4), 507-519 (2010).
63. Livraghi T, Meloni F. Treatment of hepatocellular carcinoma by percutaneous interventional methods. Hepatogastroenterology 49(43), 62-71 (2002). (Pubitemid 34289488)
64. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann. Surg. Oncol. 10(1), 52-58 (2003).
65. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J. 14(2), 117-122 (2008).
66. Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16(2), 353-357 (1992).
67. Yin XY, Xie XY, Lu MD et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer 115(9), 1914-1923 (2009).
68. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 52(2), 762-773 (2010).
69. McWilliams JP, Yamamoto S, Raman SS et al. Percutaneous ablation of hepatocellular carcinoma: Current status. J. Vasc. Interv. Radiol. 21(SUPPL8), S204-S213 (2010).
70. Lencioni R, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. Clin. Liver Dis. 9(2), 301-314 (2005).
71. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J. Clin. Oncol. 25(8), 978-986 (2007). (Pubitemid 350002864)
72. Chou CH, Chen PJ, Lee PH, Cheng AL, Hsu HC, Cheng JC. Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin. Cancer Res. 13(3), 851-857 (2007). (Pubitemid 46340359)
73. Cheng LF, Ma KF, Fan WC, Yung AW, Li TM, Wong CS. Hepatocellular carcinoma with extrahepatic collateral arterial supply. J. Med. Imaging Radiat. Oncol. 54(1), 26-34 (2010).
74. Salem R, Hunter RD. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int. J. Radiat. Oncol. Biol. Phys. 66(SUPPL2), S83-S88 (2006). (Pubitemid 44353960)
75. Boucher E, Garin E, Guylligomarc'h A, Olivié D, Boudjema K, Raoul JL. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother. Oncol. 82(1), 76-82 (2007). (Pubitemid 46110911)
76. Kojiro M. Pathology. In: Diagnosis and Treatment of Hepatocellular Carcinoma. Livraghi T, Makuuchi M, Buscarini L (Eds). Greenwich Medical Media, London, UK, 27-34 (1997).
77. Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol. Aspects Med. 31(2), 179-193 (2010).
78. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int. 25(2), 261-265 (2005).
79. Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 5(4), 495-500 (2006). (Pubitemid 44782085)
80. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: A collective review. Eur. J. Surg. Oncol. 31(4), 331-347 (2005). (Pubitemid 40521297)
81. Mazzaferro V, Majno P. Principles for the best multidisciplinary meetings. Lancet Oncol. 12(4), 323-325 (2011).